Ipsen: 13% drop in annual EPS
At 3.13 billion euros, the pharmaceutical company's total sales rose by 6.7% at constant exchange rates (+3.4% on a reported basis), driven by the performance of growth platforms and the contribution of new drugs.
For 2024, Ipsen is targeting total sales growth of over 6% at constant exchange rates and an operating margin of around 30%, including the impact of four potential launches and a strengthened R&D product portfolio.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction